- Home
- FHTX
FHTX
Foghorn Therapeutics Inc.
as 04-24-2025 4:00pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $12.57 | AVG Volume (30 days): | 140.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.94 - $10.25 | Next Earning Date: | 05-05-2025 |
| Revenue: | $22,602,000 | Revenue Growth: | -33.83% |
| Revenue Growth (this year): | 15.37% | Revenue Growth (next year): | 23.06% |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
GlobeNewswire
a month ago
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Zacks
2 months ago
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
MT Newswires
2 months ago
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late
GlobeNewswire
2 months ago
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Simply Wall St.
2 months ago
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses
Zacks
2 months ago
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
GlobeNewswire
2 months ago
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.